Market Context — Why This Technology, Why Now

The escalating global burden of cancer, coupled with advancements in genomic sequencing, is fueling a strong demand for highly specific, biomarker-driven therapies. Regulatory bodies are increasingly prioritizing accelerated pathways for drugs addressing high unmet medical needs, especially for rare or intractable cancers. This technology aligns perfectly with these trends by offering a targeted solution for RB1-positive cancers, a segment where existing treatments often fall short. Its potential for faster clinical deployment positions it to capitalize on the urgent need for effective, personalized oncology solutions worldwide.

Key Competitive Advantages
01

Maximize therapeutic efficacy with combination therapy by achieving synergistic cancer cell proliferation inhibition exceeding monotherapy with CDK4/6 and NF-κB/AKT inhibitors.

02

Enable high-precision targeting for RB1-positive cancer by enhancing treatment efficacy and advancing personalized medicine through focusing on patients with the specific RB1-positive biomarker.

03

Accelerate clinical application with existing drug combinations by shortening safety evaluations and clinical trial phases compared to novel compound development, as it combines inhibitors already in clinical use.

Market Opportunity
Oncology Therapeutics Market
$500M–$6.5B domestically, $5B–$65B globally (AI est.)
The anticancer drug market continues to grow due to an aging population and an increase in new cancer patients. There is an accelerating shift towards personalized medicine, making targeted therapies highly valuable.
Global pharmaceutical companies specializing in oncology Biotech firms developing targeted cancer therapies Contract research organizations (CROs) for clinical trials
Diagnostic Market (Biomarker Diagnostics)
$50M–$650M domestically, $0.5B–$6.5B globally (AI est.)
Biomarker diagnostics are essential for the widespread adoption of precision medicine, predicting treatment efficacy. This technology includes a diagnostic kit, positioning it for expansion in this market.
Diagnostic kit manufacturers Clinical laboratory service providers Medical device companies with molecular diagnostics portfolios
Rare and Intractable Cancer Treatment Market
$50M–$650M domestically, $0.5B–$6.5B globally (AI est.)
Therapies for rare and intractable cancers with specific genetic abnormalities address high unmet needs and are expected to command significant market value.
Specialty pharmaceutical companies for orphan drugs Academic research institutions focused on rare diseases Biotech startups innovating in precision oncology
IP Defensibility — Why Competitors Can't Replicate This
What This Patent Covers

This patent protects a pharmaceutical composition and kit for treating RB1-positive cancer, specifically combining CDK4/6 inhibitors with NF-κB or AKT inhibitors. Its strong claims were established through successful rebuttal against six prior art documents and one office action, demonstrating clear differentiation and robust scope.

Competitive White Space

This patent focuses on specific drug combinations for RB1-positive cancers. White space exists in developing novel inhibitors for the targeted pathways, exploring alternative biomarkers for patient stratification, or expanding the combination therapy approach to other cancer-driving genetic mutations not explicitly covered.

Economic Impact
~$4M/year estimated market creation potential (est.)
estimated ROI · USD · AI analysis
ROI Calculation Logic

Assuming approximately 10,000 RB1-positive cancer patients annually in Japan and an existing anticancer drug treatment cost of ~$3,350/month (AI est.), the annual treatment market could reach ~$400M (AI est.). If this combination therapy is adopted by 1% of the market, it could generate ~$4M/year (AI est.) in market value by addressing unmet needs.

Speed to Market
3× faster than in-house development
This technology is based on a combination of existing cyclin-dependent kinase (CDK) 4 and 6 inhibitors, and NF-κB or AKT inhibitors. Since these drugs are already clinically approved and in use, it may be possible to supplement some toxicity and safety evaluations with existing clinical data, compared to developing new compounds. This is expected to significantly shorten the time to market and provide patients with new treatment options sooner.
Competitive Positioning

X: Maximized Therapeutic Efficacy
Y: Target Specificity

Business Models & Applications
💊 Pharmaceutical Composition Manufacturing & Sales
Manufacture and sell this technology's combination therapy pharmaceutical composition for RB1-positive cancer patients through healthcare institutions, leveraging existing drug distribution networks.
🧬 Diagnostic Kit Provision
Develop and manufacture an RB1-positive cancer diagnostic kit, supplying it to healthcare and testing institutions. This could create synergistic effects when bundled with the therapeutic drug.
🤝 Collaborative Research & Development
Engage in collaborative R&D based on this technology to explore combination therapies for other cancer types or biomarkers, or to discover new inhibitors.
Adjacent Application Opportunities
🔬 Drug Discovery & Pharmaceuticals
Combination Therapy for Other Genetic Abnormalities
This technology's combination therapy approach could be applied to treat cancers with specific genetic abnormalities other than RB1 (e.g., RAS-mutated cancers, MYC-amplified cancers). A strategy of simultaneously inhibiting multiple signaling pathways may prove effective across various cancer types, potentially expanding the addressable market by billions of dollars.
🧬 Genetic Diagnostics
Next-Generation Sequencing Integrated Diagnostic Platform
Integrating the RB1-positive diagnostic kit with comprehensive cancer gene panel testing using Next-Generation Sequencing (NGS) could establish a precision medicine platform for a broader range of cancer patients. This could provide multi-faceted information crucial for treatment selection, potentially capturing a significant share of the ~$6.5B global biomarker diagnostics market.
🧪 Research Reagents & Tools
Combination Therapy Screening Platform
Based on this technology's concept, it could be developed into a high-throughput screening system or research reagents for evaluating the efficacy of novel drug candidates in combination therapies. Providing this to pharmaceutical companies and research institutions could accelerate drug discovery research, offering a valuable tool in a market estimated to be worth hundreds of millions.
Integration Roadmap — Estimated 40-Month Deployment
Phase 1: Preclinical Data Validation & Formulation Optimization
Duration: 8 months
Thoroughly validate existing preclinical data related to this technology's pharmaceutical composition and evaluate optimal drug ratios, administration routes, and formulation possibilities.
Phase 2: Clinical Trial Planning & Investigational Drug Manufacturing
Duration: 11 months
Develop clinical trial protocols for RB1-positive cancer patients after consultation with regulatory authorities. Concurrently, establish manufacturing processes for investigational drugs to be used in clinical trials.
Phase 3: Clinical Trial Execution & Approval Application Preparation
Duration: 21 months
Conduct Phase I through Phase III clinical trials incrementally based on the established plan. Prepare for pharmaceutical manufacturing and marketing approval applications using the trial data.
Technical Feasibility
This technology primarily focuses on combining existing drugs: CDK4/6 inhibitors, NF-κB inhibitors, and AKT inhibitors. Since the mechanisms of action and toxicity profiles of these drugs are already established, the technical hurdles are considered lower compared to developing new compounds. It is easier to apply existing pharmaceutical processes and quality control standards. Given it's a specific combination of inhibitors, it has high compatibility with existing drug screening technologies and evaluation systems, allowing adopting companies to proceed with development relatively smoothly.
Success Scenario
By adopting this technology, companies could offer a more effective treatment option for specific RB1-positive cancer patient groups compared to existing therapies. This could establish a competitive advantage in the market and secure new revenue streams. Furthermore, combining it with a diagnostic kit may build a brand image as a frontrunner in personalized medicine and serve as a stepping stone for future pipeline expansion.
Patent Record
APPLICATION NO.
特願2020-180429
REGISTRATION NO.
7579564
FILING DATE
2020/10/28
GRANT DATE
2024/10/30
EXPIRATION DATE
2040/10/28
PATENT HOLDER
国立大学法人金沢大学
Examination History
2023年10月04日
出願審査請求書
2024年08月27日
拒絶理由通知書
2024年09月18日
意見書
2024年09月18日
手続補正書（自発・内容）
2024年10月08日
特許査定